These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 22500551)

  • 1. Inotuzumab ozogamicin in the treatment of B-cell acute lymphoblastic leukemia.
    Thomas X
    Expert Opin Investig Drugs; 2012 Jun; 21(6):871-8. PubMed ID: 22500551
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inotuzumab ozogamicin as novel therapy in lymphomas.
    Wong BY; Dang NH
    Expert Opin Biol Ther; 2010 Aug; 10(8):1251-8. PubMed ID: 20528256
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inotuzumab ozogamicin in relapsed B-cell acute lymphoblastic leukemia.
    Thota S; Advani A
    Eur J Haematol; 2017 May; 98(5):425-434. PubMed ID: 28152223
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inotuzumab ozogamicin for the treatment of patients with acute lymphocytic leukemia.
    Choudhry A; O'Brien SM
    Drugs Today (Barc); 2017 Dec; 53(12):653-665. PubMed ID: 29517084
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of inotuzumab ozogamicin in the treatment of relapsed/refractory acute lymphoblastic leukemia.
    George B; Kantarjian H; Jabbour E; Jain N
    Immunotherapy; 2016 Feb; 8(2):135-43. PubMed ID: 26780449
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inotuzumab ozogamicin in the management of acute lymphoblastic leukaemia.
    Morley NJ; Marks DI
    Expert Rev Anticancer Ther; 2016; 16(2):159-64. PubMed ID: 26654587
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inotuzumab Ozogamicin: First Pediatric Approval.
    Dhillon S
    Paediatr Drugs; 2024 Jul; 26(4):459-467. PubMed ID: 38780741
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antibody-drug conjugates of calicheamicin derivative: gemtuzumab ozogamicin and inotuzumab ozogamicin.
    Ricart AD
    Clin Cancer Res; 2011 Oct; 17(20):6417-27. PubMed ID: 22003069
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The novel calicheamicin-conjugated CD22 antibody inotuzumab ozogamicin (CMC-544) effectively kills primary pediatric acute lymphoblastic leukemia cells.
    de Vries JF; Zwaan CM; De Bie M; Voerman JS; den Boer ML; van Dongen JJ; van der Velden VH
    Leukemia; 2012 Feb; 26(2):255-64. PubMed ID: 21869836
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inotuzumab ozogamicin is effective in relapsed/refractory extramedullary B acute lymphoblastic leukemia.
    Bertamini L; Nanni J; Marconi G; Abbenante M; Robustelli V; Bacci F; Matti A; Paolini S; Sartor C; Monaco SL; Fontana MC; De Polo S; Cavo M; Curti A; Martinelli G; Papayannidis C
    BMC Cancer; 2018 Nov; 18(1):1117. PubMed ID: 30442119
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inotuzumab ozogamicin for the treatment of acute lymphoblastic leukemia.
    Tvito A; Rowe JM
    Expert Opin Biol Ther; 2017 Dec; 17(12):1557-1564. PubMed ID: 29092647
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapeutic potential of CD22-specific antibody-targeted chemotherapy using inotuzumab ozogamicin (CMC-544) for the treatment of acute lymphoblastic leukemia.
    Dijoseph JF; Dougher MM; Armellino DC; Evans DY; Damle NK
    Leukemia; 2007 Nov; 21(11):2240-5. PubMed ID: 17657218
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inotuzumab Ozogamicin: First Global Approval.
    Lamb YN
    Drugs; 2017 Sep; 77(14):1603-1610. PubMed ID: 28819740
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preclinical to Clinical Translation of Antibody-Drug Conjugates Using PK/PD Modeling: a Retrospective Analysis of Inotuzumab Ozogamicin.
    Betts AM; Haddish-Berhane N; Tolsma J; Jasper P; King LE; Sun Y; Chakrapani S; Shor B; Boni J; Johnson TR
    AAPS J; 2016 Sep; 18(5):1101-1116. PubMed ID: 27198897
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inotuzumab ozogamicin: a CD22 mAb-drug conjugate for adult relapsed or refractory B-cell precursor acute lymphoblastic leukemia.
    Yurkiewicz IR; Muffly L; Liedtke M
    Drug Des Devel Ther; 2018; 12():2293-2300. PubMed ID: 30087554
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inotuzumab Ozogamicin: A Review in Relapsed/Refractory B-Cell Acute Lymphoblastic Leukaemia.
    Al-Salama ZT
    Target Oncol; 2018 Aug; 13(4):525-532. PubMed ID: 30090971
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety, pharmacokinetics, and preliminary clinical activity of inotuzumab ozogamicin, a novel immunoconjugate for the treatment of B-cell non-Hodgkin's lymphoma: results of a phase I study.
    Advani A; Coiffier B; Czuczman MS; Dreyling M; Foran J; Gine E; Gisselbrecht C; Ketterer N; Nasta S; Rohatiner A; Schmidt-Wolf IG; Schuler M; Sierra J; Smith MR; Verhoef G; Winter JN; Boni J; Vandendries E; Shapiro M; Fayad L
    J Clin Oncol; 2010 Apr; 28(12):2085-93. PubMed ID: 20308665
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inotuzumab ozogamicin in the treatment of acute lymphoblastic leukemia.
    Dahl J; Marx K; Jabbour E
    Expert Rev Hematol; 2016; 9(4):329-34. PubMed ID: 26783163
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preclinical and clinical development of inotuzumab-ozogamicin in hematological malignancies.
    Shor B; Gerber HP; Sapra P
    Mol Immunol; 2015 Oct; 67(2 Pt A):107-16. PubMed ID: 25304309
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic Leukemia.
    Kantarjian HM; DeAngelo DJ; Stelljes M; Martinelli G; Liedtke M; Stock W; Gökbuget N; O'Brien S; Wang K; Wang T; Paccagnella ML; Sleight B; Vandendries E; Advani AS
    N Engl J Med; 2016 Aug; 375(8):740-53. PubMed ID: 27292104
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.